Safety and Efficacy Study of USTRAP™ in Male Urinary Incontinence (PROSPECT)

Quanta Medical

Status: Active, not recruiting

Conditions: Urinary Incontinence

Treatments: Device: AMS 800®; Device: Ustrap®

Study type: Interventional

Funder types: Industry

Identifiers

NCT03323554

2782

Details and patient eligibility

About

Few surgical methods to treat male stress urinary incontinence have been assessed in comparative, randomised interventional studies.

Ustrap is a new adjustable-pressure 4-arm device. The artificial sphincter is currently considered the gold standard device in this field.

The aim of this randomised prospective international study is to assess the efficacy and safety of the Ustrap® device comparatively with an artificial sphincter (AMS800) in the treatment of stress urinary incontinence following prostate removal in cancer patients.

Enrollment: 20 patients

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Disease-related criteria:

• persistent urinary incontinence >= 12 months following radical prostatectomy for prostate adenocarcinoma
• presenting an indication for surgical insertion of a medical device
• 24h PAD test > 100 g per day
• controlled prostate adenocarcinoma, with PSA ≤ 1 ng/ml

Population-related criteria:

• male subjects aged 18 years and over
• having provided free, informed written consent to take part in the study
• patients independent and able to use the collar without difficulty and able to manage an artificial sphincter
• Patient able to understand and sign the consent form and to complete questionnaires
• Patient without mental impairment
• Patients belonging to or covered by Social Security.

Exclusion criteria

Disease-related criteria:

• Documented neurological bladder or history of neurological disease liable to interfere with urinary symptoms.
• Presence of urethral anastomotic stenosis preventing passage of the fiberscope at the initial endoscopy
• Severe symptomatic hyperactive or hypoactive bladder not controlled by drug therapy
• Severe constitutional haemorrhagic disease or haemophilia
• Patients presenting urinary infection not controlled
• Patients presenting severe renal failure and obstructive pathologies of the upper urinary tract with severe renal failure.
• Patients presenting deep immune deficiency
• Patient presenting recto-urethral fistula
• Patient with tumor of bladder
• Patient having bladder stones with failure of bladder stone treatment

Criteria related to incontinence treatment:

• Allergy to any of the components of the medical devices
• History of surgery to insert a medical device for treatment of incontinence (e.g. artificial sphincter, suburethral strap, continence balloons, etc.)
• History of periurethral injection of filling agents
• Inability to use either of the study devices
• Drug treatment: duloxetine or any treatment likely to modify continence results
• Not receiving and not likely to receive radiotherapy at any time throughout the 12-month follow-up period Population-related criteria
• Foreseeable unavailability during the study . Patient deprived of liberty by administrative or judicial decision or under legal guardianship
• Participation in another clinical trial in the 3 months preceding the initial visit

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

20 participants in 2 patient groups

Ustrap®

Experimental group

Description:

Ustrap is a new adjustable-pressure 4-arm device

Treatment:

Device: Ustrap®

AMS 800®

Active Comparator group

Description:

Artificial sphincter currently considered the gold standard device in this field

Treatment:

Device: AMS 800®